ARCHIVES

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Berger Named Dean At Case Western; Hayes Heads Lombardi’s Breast Programs

September 6, 1996

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

In Brief: Cowan to Direct Eppley Cancer Center; Nealon Retires From NCI Liaison Office

June 11, 1999

In Brief: George Vande Woude To Wistar institute Board; Donald Pinkel To Head Pediatric Leukemia Program

October 18, 1985

June Panel Meeting Dropped

June 3, 1977

NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy

October 26, 1984